DK2361091T3 - Galdesyre og biguanider som proteasehæmmere til bevarelse af peptiders integritet i tarmen - Google Patents

Galdesyre og biguanider som proteasehæmmere til bevarelse af peptiders integritet i tarmen Download PDF

Info

Publication number
DK2361091T3
DK2361091T3 DK09817101T DK09817101T DK2361091T3 DK 2361091 T3 DK2361091 T3 DK 2361091T3 DK 09817101 T DK09817101 T DK 09817101T DK 09817101 T DK09817101 T DK 09817101T DK 2361091 T3 DK2361091 T3 DK 2361091T3
Authority
DK
Denmark
Prior art keywords
compound
acid
peptide
pharmaceutically acceptable
factors
Prior art date
Application number
DK09817101T
Other languages
English (en)
Inventor
Glen Travers
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Application granted granted Critical
Publication of DK2361091T3 publication Critical patent/DK2361091T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (6)

1. Forbindelse til anvendelse i en fremgangsmåde til behandling af en sygdom i en menneskeeller dyrekrop ved terapi, i hvilken fremgangsmåde (i) menneske- eller dyrekroppen behandles ved administration af et eller flere terapeutiske peptider til tarmen, og (ii) forbindelsen administreres til tarmen for at hæmme nedbrydning af det ene eller flere peptider ved én eller flere serinproteaser, hvor forbindelsen er en galdesyre eller et biguanid, eller et farmaceutisk acceptabelt salt af galdesyren eller biguanidet, hvor galdesyren er udvalgt fra chenodesoxycholsyre, ursodesoxycholsyre, glycochenodesoxycholsyre og glycodesoxycholsyre, og hvor biguanidet er metformin eller phenformin, hvor det ene eller flere terapeutiske peptider er udvalgt fra insulin, calcitonin, væksthormon, væksthormonfrigivende faktorer, galanin, parathyroideahormon, peptid YY, oxyntomodulin, erythropoeitiner, kolonistimulerende faktorer, blodpladeafledte vækstfaktorer, epidermale vækstfaktorer, fibroblastvækstfaktorer, transformerende vækstfaktorer, GLP-1, GLP-2, exendin, leptin, neurotrofe faktorer, insulin-lignende vækstfaktorer, brusk-inducerende faktorer, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, interferon-gamma, interferon-la, alpha-interferoner og konjugater af et/en hvilket/hvilken som helst af ovenstående.
2. Forbindelse ifølge krav 1 til en anvendelse som defineret i krav 1, hvor forbindelsen er udvalgt fra chenodesoxycholsyre, ursodesoxycholsyre, glycochenodesoxycholsyre, glycodesoxycholsyre eller et farmaceutisk acceptabelt salt af disse forbindelser.
3. Forbindelse ifølge krav 1 til en anvendelse som defineret i krav 1, hvor forbindelsen er chenodesoxycholsyre eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse ifølge krav 1 til en anvendelse som defineret i krav 1, hvor forbindelsen er metformin eller phenformin eller et farmaceutisk acceptabelt salt af metformin eller phenformin.
5. Forbindelse ifølge krav 1 til en anvendelse som defineret i krav 1, hvor forbindelsen er metformin eller et farmaceutisk acceptabelt salt deraf.
6. Produkt eller farmaceutisk sammensætning indeholdende: (a) en forbindelse som defineret i et hvilket som helst af kravene 1 til 5, og (b) et peptid eller polypeptid, hvor (a) og (b) er fremstillet til samtidig, separat eller sekventiel indgivelse til et individ, hvor peptidet eller polypeptidet er beregnet til placering i tarmen til anvendelse i behandlingen ved terapi af en sygdom eller tilstand, der rammer individet, eller til anvendelse i forebyggelse af en sygdom eller tilstand, der rammer individet, og hvor forbindelsen er beregnet til anvendelse som en hæmmer af nedbrydningen af peptidet eller polypeptidet ved én eller flere serinproteaser, og hvor peptidet eller polypeptidet er udvalgt fra peptiderne defineret i krav 1.
DK09817101T 2008-10-01 2009-10-01 Galdesyre og biguanider som proteasehæmmere til bevarelse af peptiders integritet i tarmen DK2361091T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0817969.9A GB0817969D0 (en) 2008-10-01 2008-10-01 Pharmaceutical composition
PCT/AU2009/001305 WO2010037173A1 (en) 2008-10-01 2009-10-01 Bile acids and biguanides as protease inhibitors for preserving the integrity of peptides in the gut

Publications (1)

Publication Number Publication Date
DK2361091T3 true DK2361091T3 (da) 2015-04-20

Family

ID=40019875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09817101T DK2361091T3 (da) 2008-10-01 2009-10-01 Galdesyre og biguanider som proteasehæmmere til bevarelse af peptiders integritet i tarmen

Country Status (17)

Country Link
US (1) US9913850B2 (da)
EP (2) EP2873420A1 (da)
KR (1) KR101731656B1 (da)
CN (1) CN102307582B (da)
AU (1) AU2009299112B2 (da)
CA (1) CA2740477C (da)
DK (1) DK2361091T3 (da)
ES (1) ES2535260T3 (da)
GB (1) GB0817969D0 (da)
HK (2) HK1155376A1 (da)
IL (1) IL212050A (da)
PL (1) PL2361091T3 (da)
PT (1) PT2361091E (da)
RU (1) RU2525290C2 (da)
SI (1) SI2361091T1 (da)
WO (1) WO2010037173A1 (da)
ZA (1) ZA201102401B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101724431B1 (ko) 2015-08-19 2017-04-18 대우조선해양 주식회사 선박용 스러스터의 설치방법 및 이를 위한 얼라인먼트 결정용 지그
US20240238231A1 (en) * 2021-01-22 2024-07-18 Axcess (UK) Ltd Edta and egta for use in preserving the integrity of therapeutic compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US6156731A (en) * 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
EP0640344B1 (de) * 1993-08-30 1998-10-07 Medichemie Ag Ursodeoxycholsäure enthaltendes Arzneimittel in flüssiger Darreichungsform
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
AU1808897A (en) * 1995-12-13 1997-07-03 Dullatur Limited A calcitonin preparation
DE19845403B4 (de) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB2355009A (en) * 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
EP1750743A4 (en) * 2004-04-29 2009-07-08 Glaxosmithkline Zagreb ORAL PREPARATIONS CONTAINING BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF METABOLIC BONE DISEASES
EP2248531A1 (en) 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
AU2006249869A1 (en) * 2005-05-26 2006-11-30 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
CA2621577C (en) * 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US9333240B2 (en) 2005-09-16 2016-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for improving nutritional status, cognition and survival
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
US8242294B2 (en) * 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods

Also Published As

Publication number Publication date
PT2361091E (pt) 2015-05-20
EP2873420A1 (en) 2015-05-20
GB0817969D0 (en) 2008-11-05
RU2525290C2 (ru) 2014-08-10
WO2010037173A1 (en) 2010-04-08
CA2740477A1 (en) 2010-04-08
CN102307582A (zh) 2012-01-04
HK1155376A1 (en) 2012-05-18
KR20110128782A (ko) 2011-11-30
ZA201102401B (en) 2011-11-30
US20120035116A1 (en) 2012-02-09
CN102307582B (zh) 2015-10-07
ES2535260T3 (es) 2015-05-07
AU2009299112B2 (en) 2013-09-26
SI2361091T1 (sl) 2015-07-31
KR101731656B1 (ko) 2017-04-28
PL2361091T3 (pl) 2015-08-31
EP2361091B1 (en) 2015-01-21
CA2740477C (en) 2017-06-27
EP2361091A4 (en) 2012-05-23
US9913850B2 (en) 2018-03-13
EP2361091A1 (en) 2011-08-31
HK1209643A1 (en) 2016-04-08
AU2009299112A1 (en) 2010-04-08
RU2011117267A (ru) 2012-11-10
IL212050A0 (en) 2011-06-30
IL212050A (en) 2016-08-31

Similar Documents

Publication Publication Date Title
JP3549542B2 (ja) 経口用ペプチド薬剤
US6673574B2 (en) Oral delivery of peptides using enzyme-cleavable membrane translocators
JP5365629B2 (ja) 医薬組成物、および医薬錠剤
US8119125B2 (en) Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
JP2011032282A (ja) 改善された経口ペプチド送達
WO2018175413A1 (en) Alkaline phosphatase formulations
US20050215476A1 (en) Amidated parathyroid hormone fragments and uses thereof
US11173124B2 (en) Oral delivery of GLP-1 peptide analogs
EP1781312A2 (en) Formulations and methods for modulating satiety
DK2361091T3 (da) Galdesyre og biguanider som proteasehæmmere til bevarelse af peptiders integritet i tarmen
WO2009126132A1 (en) Formulations and methods for modulating satiety
JP4476544B6 (ja) 酵素で切断可能な膜トランスロケーターを用いて改善されたペプチドの経口送達
JP2024509829A (ja) Ｇｌｐ－１受容体作動薬を経口投与するための医薬組成物
DK1339431T3 (da) Forbedret oral indgivelse af peptider under anvendelse af enzym-spaltelige membrantranslokatorer